Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 725 shares at $26.59 ($19K) on 2025-08-19, disclosed to the SEC on 2025-08-21.
Seasonal sale ($19k) by Chief R&D Officer — this insider has traded NKTR in August in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| NKTR | SELL | 2026-06-17 | $336K | — | Filing → |
| NKTR | SELL | 2026-05-21 | $13K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $13K | — | Filing → |